PAM
MLYS icon

Panagora Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Panagora Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,016
Closed -$392K – 1281
2023
Q2 		$392K Buy
+23,016
New +$344K ﹤0.01% 1031

Other funds holding MLYS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Panagora Asset Management's MLYS Position: Q3 2023 in Review

Panagora Asset Management sold out of Mineralys Therapeutics (MLYS) in Q3 2023, closing a stake of 23,016 shares — an estimated $392K sold.

Panagora Asset Management first reported a position in MLYS in Q2 2023 and held it in 1 quarter. The position peaked at $392K in Q2 2023. 77 funds tracked by Wall St. Rank hold MLYS as of Q3 2023.

  • Panagora Asset Management reported no remaining Mineralys Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Panagora Asset Management sold 23,016 Mineralys Therapeutics shares in Q3 2023, an estimated $392K.
  • Panagora Asset Management first reported a position in Mineralys Therapeutics in Q2 2023 and held it in 1 quarter.
  • Panagora Asset Management's Mineralys Therapeutics position peaked at $392K in Q2 2023.
  • 77 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2023.

Based on Panagora Asset Management's 13F filing for Q3 2023, filed 31 Oct 2023.